Beam generated $175 million in premiums last year, and the deal targets Principal's specialty benefits 5-9% growth range ...
Principal Financial Group® (Nasdaq: PFG) announced today an agreement to acquire Beam Benefits, an employee benefits company ...
An independent arbitration panel ruled that developing Prime Medicine’s experimental drug for Alpha-1 Antitrypsin Deficiency ...
Prime Medicine has come out ahead in its patent dispute with fellow gene editing biotech Beam Therapeutics, after a panel of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results